Mette Aaskov Ulbak serves as Director, Regulatory Affairs at Hemab. She possess a wealth of experience developing products for rare diseases with multiple therapeutic modalities including gene therapy. Her work spans early phase to submission of marketing authorization applications leading to approval. She has worked at both small and large organizations, including Lundbeck, Ovid Therapeutics, Prevail Therapeutics, Ascendis Pharma and most recently at Adrenomed AG, where she was the Head of Regulatory Affairs. Mette holds a Master in Pharmaceutical Sciences from the University of Copenhagen, Denmark.